MAST1

Microtubule-associated serine/threonine-protein kinase 1 · Q9Y2H9 · MAST1 on Sugi Atlas →

0 patent compounds predicted against MAST1, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to MAST1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment PHASE3UNKNOWN
Masitinib in Combination With Riluzole for the Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS) PHASE2/PHASE3COMPLETED
Efficacy and Safety of Masitinib in the Treatment of Progressive Multiple Sclerosis PHASE3COMPLETED
Interest of Denosumab Treatment in Osteoporosis Associated to Systemic Mastocytosis PHASE3COMPLETED
Hydroxychloroquine in Isolated Cutaneous Mastocytosis Patients or Indolent Systemic Mastocytosis With Associated Skin Involvement Patients PHASE2/PHASE3UNKNOWN
Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis PHASE3COMPLETED
Masitinib in Patients With Mild to Moderate Alzheimer's Disease PHASE3COMPLETED
Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients PHASE3RECRUITING
Masitinib in Patients With Mild Alzheimer's Disease PHASE3NOT_YET_RECRUITING
Efficacy and Safety of Masitinib in Combination With SoC Versus Placebo in the Treatment of ALS Patients PHASE3NOT_YET_RECRUITING
Masitinib for the Treatment of Severe Mast Cell Activation Syndrome PHASE2UNKNOWN
A Randomized, Double-Blind, Placebo-Controlled Study of Omalizumab for Idiopathic Anaphylaxis PHASE2COMPLETED
Phase 2 Midostaurin in Aggressive Systemic Mastocytosis and Mast Cell Leukemia PHASE2COMPLETED
Study of Sting Challenge and Serological Responses to Jack Jumper Venom Immunotherapy With Inulin as Adjuvant (Jumpvax) PHASE1/PHASE2UNKNOWN
Midostaurin in Indolent Systemic Mastocytosis PHASE2UNKNOWN
Allergy and Immunology Natural History Study nanRECRUITING
Cause and Natural Course of Pediatric-Onset Mastocytosis nanCOMPLETED
Blood Factors in Mastocytosis and Unexplained Anaphylaxis and Flushing nanCOMPLETED
Cytokine Production Patterns in Patients With Systemic Mastocytosis Compared With Atopic Dermatitis and Healthy Individuals nanCOMPLETED
Cause of Unexplained Anaphylaxis nanACTIVE_NOT_RECRUITING
Cutaneous Mastocytosis in Children: Analysis of Somatic and Germline Mutations nanCOMPLETED
Mast Cell Connect: A Registry for Patients With Mastocytosis nanCOMPLETED
Study of Factors Regulating Mast Cell Proliferation nanRECRUITING
Relationship Between Circulating Sclerostin and Bone Lesions in Patients With Mastocytosis nanRECRUITING
Pathogenesis of Physical Induced Urticarial Syndromes nanCOMPLETED
Screening Protocol for Genetic Diseases of Allergic Inflammation nanCOMPLETED
Role of Tryptase Levels in Patients With Stable Coronary Artery Disease. nanRECRUITING
Natural History Study of Mitochondrial Myopathy nanRECRUITING
Study of Cellular Heterogeneity in Patients With Mastocytosis nanNOT_YET_RECRUITING
In Vivo Assessment of Histamine Pharmacodynamics nanWITHDRAWN

Related proteins — ESM-2 sequence neighbours (a MAST1 binder may also engage these)

ProteinNameSimilarity
Q9R1L5 1.000 Q9R1L5 →
Q810W7 1.000 Q810W7 →
Q6P0Q8 0.998 Q6P0Q8 →
MAST3 Microtubule-associated serine/threonine-protein kinase 3 0.998 landscape →
Q3U214 0.998 Q3U214 →
Q811L6 0.995 Q811L6 →
Q6AX33 0.994 Q6AX33 →
Q924U5 0.994 Q924U5 →
Q60592 0.994 Q60592 →
MAP3K13 Mitogen-activated protein kinase kinase kinase 13 0.994 landscape →
Q3ULB5 0.993 Q3ULB5 →
Q60610 0.993 Q60610 →
Q2PFD7 0.992 Q2PFD7 →
MAP3K9 Mitogen-activated protein kinase kinase kinase 9 0.992 landscape →
Q63553 0.992 Q63553 →
Q641K5 0.992 Q641K5 →
Q9BQK8 0.992 Q9BQK8 →
Q60700 0.992 Q60700 →
Q5R8X7 0.991 Q5R8X7 →
A2AHC3 0.991 A2AHC3 →
O70405 0.991 O70405 →
A7MBB4 0.991 A7MBB4 →
Q9P202 0.991 Q9P202 →
A0A0G2JUG7 0.991 A0A0G2JUG7 →
A6QP06 0.991 A6QP06 →
Q92539 0.991 Q92539 →
MAST4 Microtubule-associated serine/threonine-protein kinase 4 0.990 landscape →
Q9BQI7 0.990 Q9BQI7 →
A8XQD5 0.990 A8XQD5 →
Q8R0S2 0.990 Q8R0S2 →